Ipilimumab and its toxicities: a multidisciplinary approach.

Oncologist 2013 Jun 17;18(6):733-43. Epub 2013 Jun 17.

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, USA.

The treatment for metastatic melanoma has evolved significantly in the past few years. Ipilimumab, an immunotherapy, is now in mainstream oncology practice given that it has shown improved overall survival in randomized clinical trials. Other immune modulating agents, such as programmed death receptor-1 and programmed death receptor ligand-1 antibodies, are showing promise in early clinical trials. This manuscript will review ipilimumab and its most common side effects. Immune-related adverse events (irAEs) are important to recognize early, and their presentation, timing of onset, and general recommendations for workup and management will be reviewed. Assembling a multidisciplinary team, as well as thorough education of the patient, is recommended to optimize patient care.

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2012-0483DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063401PMC
June 2013
5 Reads

Publication Analysis

Top Keywords

clinical trials
8
programmed death
8
ipilimumab common
4
common side
4
review ipilimumab
4
side effects
4
effects immune-related
4
events iraes
4
adverse events
4
immune-related adverse
4
will review
4
trials manuscript
4
receptor ligand-1
4
death receptor
4
receptor-1 programmed
4
death receptor-1
4
ligand-1 antibodies
4
antibodies showing
4
iraes recognize
4
promise early
4

Similar Publications